摘要
乳腺癌目前已成为全球发病率最高的恶性肿瘤,乳腺癌防治工作仍面临巨大挑战。随着乳腺癌分子分型诊疗模式的建立和治疗药物的更新迭代,乳腺癌内科治疗已经形成化疗、靶向治疗、内分泌治疗和免疫治疗融合的成熟体系。中国乳腺癌患者基数大,疾病的发生、发展有其独特的临床特征,因此,研发适合中国人群的药物及探索合适的治疗方式,对提高乳腺癌患者生存期,改变乳腺癌治疗格局尤为重要。近年来,中国临床工作者在乳腺癌治疗领域取得了重要突破,本文将全面回顾一年来中国乳腺癌临床研究的重要进展,以期更好地指导乳腺癌的规范化诊疗。
Breast cancer has become the most diagnosed cancer in the world.The prevention and treatment of breast cancer still faces great challenges.With the establishment of diagnosis and treatment model based on molecular subtyping of breast cancer and the development of new therapeutic drugs,the medical treatment of breast cancer has formed a mature system integrated of chemotherapy,targeted therapy,endocrine therapy and immunotherapy.Because of the large number of breast cancer patients in China and their distinctive clinical characteristics in oncogenesis and progression,it is important to develop new drugs and explore appropriate treatment approaches suitable for the Chinese population in order to improve the survival benefits and change treatment pattern.In recent years,Chinese clinicians have achieved significant breakthroughs in breast cancer treatment.This article has reviewed the noteworthy advancement of clinical research on breast cancer in China in the past year,aiming to provide guidance for standardized diagnosis and treatment of breast cancer.
作者
刘佳璇
徐兵河
Liu Jiaxuan;Xu Binghe(Department of Internal Medicine,National Cancer Center/National Clinical Research Center for Oncology/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《中华乳腺病杂志（电子版）》
CAS
CSCD
2023年第5期259-265,共7页
Chinese Journal of Breast Disease(Electronic Edition)
基金
中国医学科学院医学与健康科技创新工程资助项目(2021-12M-1-014、2022-12M-JB-009)。
关键词
乳腺肿瘤
临床研究
激素受体
Breast neoplasms
Clinical research
Hormone receptor
